NMD Pharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 64

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $79.8M

  • Investors
  • 8

NMD Pharma General Information

Description

Operator of a clinical-stage biotech company intended to design drugs and therapeutics for the treatment of neuromuscular disorders. The company's drugs help to strengthen neuromuscular transmission and muscle function in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical needs, enabling improvement in the quality of life and survival of patients with neuromuscular disorders.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Palle Juul-Jensens Boulevard 82
  • Aarhus N
  • 8200 Aarhus
  • Denmark
+45 52
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Palle Juul-Jensens Boulevard 82
  • Aarhus N
  • 8200 Aarhus
  • Denmark
+45 52

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NMD Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series B) 15-Nov-2023 $79.8M Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A2) 15-Feb-2022 Completed Clinical Trials - Phase 2
6. Grant 01-Jan-2022 Completed Clinical Trials - Phase 2
5. Grant 30-Nov-2020 Completed Clinical Trials - General
4. Early Stage VC (Series A) 23-Mar-2018 Completed Clinical Trials - General
3. Seed Round 13-Jun-2016 Completed Clinical Trials - General
2. Seed Round $3.79M $3.79M Completed Startup
1. University Spin-Out 01-Jan-2015 Completed Startup
To view NMD Pharma’s complete valuation and funding history, request access »

NMD Pharma Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
Preference
Preference 156,794 $23.7 $23.7 1x $23.7 3.64%
Preference 125,000 $22.79 $22.79 1x $22.79 2.9%
To view NMD Pharma’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NMD Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a clinical-stage biotech company intended to design drugs and therapeutics for the treatment of neuromuscula
Drug Discovery
Aarhus, Denmark
64 As of 2026

Basel, Switzerland

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NMD Pharma Competitors (58)

One of NMD Pharma’s 58 competitors is Baliopharm, a Venture Capital-Backed company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Baliopharm Venture Capital-Backed Basel, Switzerland
NGM Biopharmaceuticals Private Equity-Backed South San Francisco, CA
Neurona Therapeutics Formerly VC-backed South San Francisco, CA
CuraSen Venture Capital-Backed San Carlos, CA
Neurogene Formerly VC-backed New York, NY
You’re viewing 5 of 58 competitors. Get the full list »

NMD Pharma Patents

NMD Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026190100-A1 A chloride ion channel 1 inhibitor for use in disease modifying effects in the treatment of a neuromuscular disease Pending 14-Mar-2025
WO-2025196186-A1 Compounds for the treatment of neuromuscular disorders Pending 20-Mar-2024
WO-2025196206-A1 Compounds for the treatment of neuromuscular disorders Pending 20-Mar-2024
AU-2024311729-A1 Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases Pending 20-Jun-2023
EP-4731200-A1 Clc-1 inhibitors for use in the treatment of multiple sclerosis and neuromuscular diseases Pending 20-Jun-2023 A61K31/192
To view NMD Pharma’s complete patent history, request access »

NMD Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NMD Pharma Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jeito Growth/Expansion Minority
INCUBA Accelerator/Incubator
Innovationsfonden Accelerator/Incubator
Inkef Venture Capital Minority
Roche Venture Fund Corporate Venture Capital Minority
You’re viewing 5 of 8 investors. Get the full list »

NMD Pharma FAQs

  • When was NMD Pharma founded?

    NMD Pharma was founded in 2015.

  • Where is NMD Pharma headquartered?

    NMD Pharma is headquartered in Aarhus, Denmark.

  • What is the size of NMD Pharma?

    NMD Pharma has 64 total employees.

  • What industry is NMD Pharma in?

    NMD Pharma’s primary industry is Drug Discovery.

  • Is NMD Pharma a private or public company?

    NMD Pharma is a Private company.

  • What is NMD Pharma’s current revenue?

    The current revenue for NMD Pharma is .

  • How much funding has NMD Pharma raised over time?

    NMD Pharma has raised $173M.

  • Who are NMD Pharma’s investors?

    Jeito, INCUBA, Innovationsfonden, Inkef, and Roche Venture Fund are 5 of 8 investors who have invested in NMD Pharma.

  • Who are NMD Pharma’s competitors?

    Baliopharm, NGM Biopharmaceuticals, Neurona Therapeutics, CuraSen, and Neurogene are some of the 58 competitors of NMD Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process